This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Siegel-Lakhai, W. S. Articles by Schellens, J. H.M. Search for Related Content PubMed PubMed Citation Articles by Siegel-Lakhai, W. S. Articles by Schellens, J. H.M.

Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva^®) and Gefitinib (Iressa^®)

^a The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; ^b Slotervaant Hospital, Amsterdam, The Netherlands; ^c Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, Utrecht University, Utrecht, The Netherlands

Correspondence: Wandena S. Siegel-Lakhai, The Netherlands Cancer Institute, Department of Medical Oncology/Department of Pharmacy and Pharmacology, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. Telephone: 31-0-20-512-4481; e-mail: apwla{at}slz.nl

Gefitinib (Iressa^®; AstraZeneca Pharmaceuticals, Wilmington, DE, http://www.astrazeneca-us.com) and erlotinib (Tarceva^®; OSI Pharmaceuticals, Inc., Melville, NY, http://www.osip.com) are so-called small molecules that selectively inhibit epidermal growth factor receptor (EGFR) tyrosine kinase activity. Both drugs received registration approval by the U.S. Food and Drug Administration (FDA) for the second- and third-line treatment of non-small cell lung cancer (NSCLC), but the failure of gefitinib to show a survival advantage over placebo has resulted in a discussion about the registration of gefitinib. Recently published results have revealed that mutations in the tyrosine kinase domain of EGFR are strongly associated with increased gefitinib and erlotinib sensitivity in patients with advanced NSCLC. Here, we present the current knowledge and the future directions of the EGFR tyrosine kinase inhibitors gefitinib and erlotinib.

Key Words. EGFR tyrosine kinase inhibitors • Gefitinib • Erlotinib • Targeted therapy • EGFR tyrosine kinase domain mutations

This article has been cited by other articles:

				J B Arnes, L R Begin, I Stefansson, J-S Brunet, T O Nielsen, W D Foulkes, and L A Akslen Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer J. Clin. Pathol., February 1, 2009; 62(2): 139 - 146. [Abstract] [Full Text] [PDF]

				M. Michaelis, J. Bliss, S. C. Arnold, N. Hinsch, F. Rothweiler, H. E. Deubzer, O. Witt, K. Langer, H. W. Doerr, W. S. Wels, et al. Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins Clin. Cancer Res., October 15, 2008; 14(20): 6531 - 6537. [Abstract] [Full Text] [PDF]

				L C Huber, P Kunzler, S H Boyce, B A Michel, R E Gay, B S Ink, and S Gay Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts Ann Rheum Dis, March 1, 2008; 67(3): 389 - 394. [Abstract] [Full Text] [PDF]

				R. Tongbai, G. Idelman, S. H. Nordgard, W. Cui, J. L. Jacobs, C. M. Haggerty, S. J. Chanock, A.-L. Borresen-Dale, G. Livingston, P. Shaunessy, et al. Transcriptional Networks Inferred from Molecular Signatures of Breast Cancer Am. J. Pathol., February 1, 2008; 172(2): 495 - 509. [Abstract] [Full Text] [PDF]

				K. J. Hare, B. Hartmann, H. Kissow, J. J. Holst, and S. S. Poulsen The Intestinotrophic Peptide, GLP-2, Counteracts Intestinal Atrophy in Mice Induced by the Epidermal Growth Factor Receptor Inhibitor, Gefitinib Clin. Cancer Res., September 1, 2007; 13(17): 5170 - 5175. [Abstract] [Full Text] [PDF]

				J. Li, M. Zhao, P. He, M. Hidalgo, and S. D. Baker Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes Clin. Cancer Res., June 15, 2007; 13(12): 3731 - 3737. [Abstract] [Full Text] [PDF]

				T. G. Johns, R. M. Perera, S. C. Vernes, A. A. Vitali, D. X. Cao, W. K. Cavenee, A. M. Scott, and F. B. Furnari The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization Clin. Cancer Res., March 15, 2007; 13(6): 1911 - 1925. [Abstract] [Full Text] [PDF]

				P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor Clin. Cancer Res., March 1, 2007; 13(5): 1540 - 1551. [Abstract] [Full Text] [PDF]

				X. Zhang and A. Chang Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer J. Med. Genet., March 1, 2007; 44(3): 166 - 172. [Abstract] [Full Text] [PDF]

				S. M. Wiseman, H. Masoudi, P. Niblock, D. Turbin, A. Rajput, J. Hay, S. Bugis, D. Filipenko, D. Huntsman, and B. Gilks Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment Ann. Surg. Oncol., February 1, 2007; 14(2): 719 - 729. [Abstract] [Full Text] [PDF]